[Federal Register Volume 76, Number 49 (Monday, March 14, 2011)]
[Notices]
[Pages 13623-13626]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-5739]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0116]


Agency Information Collection Activities; Proposed Collection; 
Comment Request; Medical Device Labeling Regulations

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
opportunity for public comment on the proposed collection of certain 
information by the Agency. Under the Paperwork Reduction Act of 1995 
(the PRA), Federal Agencies are required to publish notice in the 
Federal Register concerning each proposed collection of information, 
including each proposed extension of an existing collection of 
information, and to allow 60 days for public comment in response to the 
notice. This notice solicits comments on medical device labeling 
regulations.

DATES: Submit either electronic or written comments on the collection 
of information by May 13, 2011.

ADDRESSES: Submit electronic comments on the collection of information 
to http://www.regulations.gov. Submit written comments on the 
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852. All comments should be identified with the docket 
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of 
Information Management, PI50-400B, Food and Drug Administration, 1350 
Piccard Dr., Rockville, MD 20850, 301-796-5156, 
<a href="/cdn-cgi/l/email-protection#6125000f08040d4f260815150d04120e0f210705004f0909124f060e17"><span class="__cf_email__" data-cfemail="377356595e525b19705e43435b5244585977515356195f5f4419505841">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal 
Agencies must obtain approval from the Office of Management and Budget 
(OMB) for each collection of information they conduct or sponsor. 
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 
1320.3(c) and includes Agency requests or requirements that members of 
the public submit reports, keep records, or provide information to a 
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) 
requires Federal Agencies to provide a 60-day notice in the Federal 
Register concerning each proposed collection of information, including 
each proposed extension of an existing collection of information before 
submitting the collection to OMB for approval. To comply with this 
requirement, FDA is publishing notice of the proposed collection of 
information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.

Medical Device Labeling Regulations--(OMB Control Number 0910-0485)--
(Extension)

    Section 502 of the Federal Food, Drug, and Cosmetic Act (the FD&C 
Act) (21 U.S.C. 352), among other things, establishes requirements for 
the label or labeling of a medical device so that it is not misbranded 
and subject to a

[[Page 13624]]

regulatory action. Certain provisions under section 502 require 
manufacturers, importers, and distributors of medical devices to 
disclose information about themselves or the devices, on the labels or 
labeling for the devices. Section 502(b) of the FD&C Act requires that 
for packaged devices, the label must bear the name and place of 
business of the manufacturer, packer, or distributor as well as an 
accurate statement of the quantity of the contents. Section 502(f) of 
the FD&C Act requires that the labeling for a device must contain 
adequate directions for use. FDA may however, grant an exemption, if 
the Agency determines that the adequate directions for use labeling 
requirements are not necessary for the particular case, as it relates 
to protection of the public health.
    FDA regulations under parts 800, 801, and 809 (21 CFR parts 800, 
801, and 809) require disclosure of specific information by 
manufacturers, importers, and distributors of medical devices about 
themselves or the devices, on the label or labeling for the devices to 
health professionals and consumers. FDA issued these regulations under 
the authority of sections 201, 301, 502, and 701 of the FD&C Act (21 
U.S.C. 321, 331, 352, and 371). Most of the regulations under parts 
800, 801, and 809 are derived from requirements of section 502 of the 
FD&C Act, which provides in part, that a device shall be misbranded if 
among other things, its label or labeling fails to bear certain 
required information concerning the device, is false or misleading in 
any particular way, or fails to contain adequate directions for use.

Reporting Burden

    Sections 800.10(a)(3) and 800.12(c) require that the label for 
contact lens cleaning solutions bear a prominent statement alerting 
consumers of the tamper-resistant feature. Further, Sec.  800.12 
requires that packaged contact lens cleaning solutions contain a 
tamper-resistant feature, to prevent malicious adulteration.
    Section 800.10(b)(2) requires that the labeling for liquid 
ophthalmic preparations packed in multiple-dose containers provide 
information on the duration of use and the necessary warning 
information to afford adequate protection from contamination during 
use.
    Section 801.1 requires that the label for a device in package form, 
contain the name and place of business of the manufacturer, packer, or 
distributor.
    Section 801.5 requires that labeling for a device include 
information on intended use as defined under Sec.  801.4 and provide 
adequate directions to assure safe use by the lay consumers.
    Section 801.61 requires that the principal display panel of an 
over-the-counter (OTC) device in package form must bear a statement of 
the identity of the device. The statement of identity of the device 
must include the common name of the device followed by an accurate 
statement of the principal intended actions of the device.
    Section 801.62 requires that the label for an OTC device in package 
form must bear a statement of declaration of the net quantity of 
contents. The label must express the net quantity in terms of weight, 
measure, numerical count, or a combination of numerical count and 
weight, measure, or size.
    Section 801.109 establishes labeling requirements for prescription 
devices, in which the label for the device must describe the 
application or use of the device, and contain a cautionary statement 
restricting the device for sale by, or on the order of an appropriate 
professional.
    For prescription by a licensed practitioner, Sec.  801.110 
establishes labeling requirements for a prescription device delivered 
to the ultimate purchaser or user. The device must be accompanied by 
labeling bearing the name and address of the licensed practitioner, 
directions for use, and cautionary statements if any, provided by the 
order.
    Section 801.150(e) requires a written agreement between firms 
involved when a nonsterile device is assembled or packaged with 
labeling that identifies the final finished device as sterile, for 
which the device is ultimately introduced into interstate commerce to 
an establishment or contract manufacturer to be sterilized. When a 
written agreement complies with the requirements under Sec.  
801.150(e), FDA takes no regulatory action against the device as being 
misbranded or adulterated. In addition, Sec.  801.150(e) requires that 
each pallet, carton, or other designated unit, be conspicuously marked 
to show its nonsterile nature when introduced into interstate commerce, 
and while being held prior to sterilization.
    Section 801.405(b)(1) provides for labeling requirements for 
articles, including repair kits, re-liners, pads, and cushions, 
intended for use in temporary repairs and refitting of dentures for lay 
persons. Section 801.405(b)(1) also requires that the labeling contain 
the word ``emergency'' preceding and modifying each indication-for-use 
statement for denture repair kits and the word ``temporary'' preceding 
and modifying each indication-for-use statement for re-liners, pads, 
and cushions.
    Section 801.405(c) provides for labeling requirements that contain 
essentially the same information described under Sec.  801.405(b)(1). 
The information is intended to enable a lay person to understand the 
limitations of using OTC denture repair kits, and denture re-liners, 
pads, and cushions.
    Section 801.420(c)(1) requires that manufacturers or distributors 
of hearing aids develop a user instructional brochure to be provided by 
the dispenser of the hearing aid to prospective users. The brochure 
must contain detailed information on the use and maintenance of the 
hearing aid.
    Section 801.420(c)(4) establishes requirements that the user 
instructional brochure or separate labeling, provide for technical data 
elements useful for selecting, fitting, and checking the performance of 
a hearing aid. In addition, Sec.  801.420(c)(4) provides for testing 
requirements to determine that the required data elements must be 
conducted in accordance with the American National Standards 
Institute's (ANSI) ``Specification of Hearing Aid Characteristics,'' 
ANSI S3.22-1996 (ASA 70-1996); (Revision of ANSI S3.22-1987), which is 
incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR 
part 51.
    Section 801.421(b) establishes requirement for the hearing aid 
dispenser to provide prospective users with a copy of the user 
instructional brochure along with an opportunity to review comments, 
either orally or by the predominant method of communication used during 
the sale.
    Section 801.421(c) establishes requirements for the hearing aid 
dispenser to provide a copy of the user instructional brochure to the 
prospective purchaser of any hearing aid upon request or, if the 
brochure is unavailable, provide the name and address of the 
manufacturer or distributor from which it may be obtained.
    Section 801.430(d) establishes labeling requirements for menstrual 
tampons to provide information on signs, risk factors, and ways to 
reduce the risk of Toxic Shock Syndrome (TSS).
    Section 801.430(e)(2) requires menstrual tampon package labels to 
provide information on the absorbency term based on testing required 
under Sec.  801.430(f) and an explanation of selecting absorbencies 
that reduce the risk of contracting TSS.
    Section 801.430(f) establishes requirements that manufacturers of

[[Page 13625]]

menstrual tampons devise and follow an ongoing sampling plan for 
measuring the absorbency of menstrual tampons. Further, manufacturers 
must use the method and testing parameters described under Sec.  
801.430(f).
    Section 801.435(b), (c), and (h) establishes requirements for 
condom labeling to bear an expiration date that is supported by testing 
that demonstrates the integrity of three random lots of the product.
    Section 809.10(a) and (b) establishes requirements that a label for 
an in vitro diagnostic device and the accompanying labeling (package 
insert), must contain information identifying its intended use, 
instructions for use and lot or control number, and source.
    Section 809.10(d)(1) provides that the labeling requirements for 
general purpose laboratory reagents may be exempt from the requirements 
of Sec.  809.10(a) and (b), if the labeling contains information 
identifying its intended use, instructions for use, lot or control 
number, and source.
    Section 809.10(e) provides that the labeling for ``Analytic 
Specific Reagents'' (ASRs) must provide information identifying the 
quantity or proportion or each reagent ingredient, instructions for 
use, lot or control number, and source.
    Section 809.10(f) provides that the labeling for OTC test sample 
collection systems for drugs of abuse must include information on the 
intended use, specimen collection instructions, identification system, 
and information about use of the test results. In addition, Sec.  
809.10(f) requires that this information be in a language appropriate 
for the intended users.
    Section 809.30(d) requires that advertising and promotional 
materials for ASRs include the identity and purity of the ASR and the 
identity of the analyte.
    Section 1040.20(d) provides that manufacturers of sunlamp products 
and ultraviolet lamps are subject to the labeling regulations under 
part 801.

Recordkeeping Burden

    Section 801.150(a)(2) establishes recordkeeping requirements for 
reprocessors, relabelers, or repackagers to retain a copy of the 
agreement containing the specifications for the processing, labeling, 
or repacking of the device for 2 years after the shipment or delivery 
of the device. Section 801.150(a)(2) also requires that the subject 
respondents make copies of this agreement available for inspection at 
any reasonable hour to any officer or employee of the Department of 
Health and Human Services (HHS), upon their request.
    Section 801.421(d) establishes requirements for hearing aid 
dispensers to retain copies of all physician statements or any waivers 
of medical evaluation for 3 years after dispensing the hearing aid.
    Section 801.410(e) requires copies of invoices, shipping documents, 
and records of sale or distribution of all impact resistant lenses, 
including finished eyeglasses and sunglasses, be maintained for 3 years 
by the retailer and made available upon request by any officer or 
employee of FDA or by any other officer or employee acting on behalf of 
the Secretary of HHS.
    Section 801.410(f) requires that the results of impact tests and 
description of the test method and apparatus be retained for a period 
of 3 years.
    Section 801.421(d) requires hearing aid dispensers to retain a copy 
of any written statement from a physician required under Sec.  
801.421(a)(1), or any written statement waiving medical evaluation 
required under Sec.  801.421(a)(2)(iii) for 3 years after the 
dispensing the hearing aid.
    Section 801.435(g) requires latex condom manufacturers to document 
and provide, upon request, an appropriate justification for the 
application of the testing data from one product on any variation of 
that product to support expiration dating in the user labeling.
    FDA estimates the burden of this collection of information as 
follows:

                                                     Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                        Number of    Annual frequency   Total annual       Hours per
                           21 CFR Section                              respondents      of response       responses         response        Total hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
800.10(a)(3) and 800.12(c).........................................              37             100             3,700               1              3,700
800.10(b)(2).......................................................              37             100             3,700               1              3,700
801.1..............................................................          23,393               6           140,358                .1          140,036
801.5..............................................................           5,000               3.5          17,500              22.35         391,125
801.61.............................................................           5,000               3.5          17,500               1             17,500
801.62.............................................................           1,000               5             5,000               1              5,000
801.109............................................................          18,000               3.5          63,000              17.77       1,119,510
801.110............................................................          10,000              50           500,000               0.25         125,000
801.150(e).........................................................              90              20             1,800               4              7,200
801.405(b)(1)......................................................              99               1.7             168               4                673
801.405(c).........................................................              99               1.7             168               4                673
801.420(c)(1)......................................................             275               5             1,375              40             55,000
801.420(c)(4)......................................................             275               5             1,375              80            110,000
801.421(b).........................................................          10,000             160         1,600,000               0.30         480,000
801.421(c).........................................................          10,000               5            50,000               0.17           8,500
801.430(d).........................................................              45               2                90               2                180
801.430(e)(2)......................................................              45               2                90               2                180
801.430(f).........................................................              45               2                90              80              7,200
801.435(b), (c), and (h)...........................................              86               3.4             292             100             29,200
809.10(a) and (b)..................................................           1,700               6            10,200              80            816,000
809.10(d)(1).......................................................             300               2               600              40             24,000
809.10(e)..........................................................             300              25             7,500               1              7,500
809.10(f)..........................................................              20               1                20             100              2,000
809.30(d)..........................................................             300              25             7,500               1              7,500
1040.20(d).........................................................             110               1               110              10              1,100
                                                                    ------------------------------------------------------------------------------------
    Total..........................................................  ..............  ................  ..............  .................       3,362,477
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.


[[Page 13626]]


                           Table 2--Estimated Average Annual Recordkeeping Burden \1\
----------------------------------------------------------------------------------------------------------------
                                                      Annual
         21 CFR section              Number of     frequency of    Total annual      Hours per      Total hours
                                   recordkeepers   recordkeeping      records         record
----------------------------------------------------------------------------------------------------------------
801.150(a)(2)...................              57               1              57          0.50                29
801.410(e) and (f)..............              30         924,100      27,723,000          0.0008          22,178
801.421(d)......................          10,000             160       1,600,000          0.25           400,000
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............  ..............  ..............         422,207
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.

    The medical device labeling regulations also refer to previously 
approved collections of information found in FDA regulations. The 
collections of information under Sec.  800.12(d) and 801.437(i) have 
been approved under OMB control number 0910-0183; the collections of 
information under Sec.  800.12(e) have been approved under OMB control 
number 0910-0231; and the collections of information under Sec.  
801.435(g) have been approved under OMB control number 0910-0073.
    Further, FDA concludes that labeling statements under Sec. Sec.  
801.63, 801.405(b)(2) and (b)(3), 801.420(c)(2) and (c)(3), 801.430(c) 
and (e)(1), 801.433, 801.437(d) through (g), and 809.30(d)(2), (d)(3), 
and (e) do not constitute a ``collection of information'' under the 
PRA. Rather, these labeling statements are ``public disclosure'' of 
information originally supplied by the Federal Government to the 
recipient for the purpose of ``disclosure to the public'' (5 CFR 
1320.3(c)(2)).

Reporting

    These estimates are based on FDA's registration and listing 
database for medical device establishments and FDA's knowledge of and 
experience with device labeling.

Recordkeeping

    These estimates are based on FDA's registration and listing 
database for medical device establishments, Agency communications with 
industry, and FDA's knowledge of and experience with device labeling.
    The medical device labeling regulations also refer to previously 
approved collections of information. The collections of information 
under Sec. Sec.  800.12(d) and 801.437(i) have been approved under OMB 
control number 0910-0183; and the collections of information under 
Sec.  800.12(e) have been approved under OMB control number 0910-0231.
    The information collection requirements under Sec. Sec.  801.63, 
801.405(b)(2) and (b)(3), 801.420(c)(2) and (c)(3), 801.430(c) and 
(e)(1), 801.433, 801.437(d) through (g), and 809.30(d)(2), (d)(3), (e) 
are not considered information collection because the public 
information is originally supplied by the Federal Government to the 
recipient for the purpose of disclosure to the public (5 CFR 
1320.3(c)(2)).

    Dated: March 4, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-5739 Filed 3-11-11; 8:45 am]
BILLING CODE 4160-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>